webpage w links:
http://www.tmdlab.com/tmdnews_abstracts.htm
Upcoming Scientific Presentations
ASCO 06 – “Heterogeneity of epidermal growth factor receptor (EGFR) expression and variation in immunohistochemistry IHC testing may affect access to EGFR-targeted therapy in patients with advanced colorectal cancer (CRC)”
ASCO 06 “Therapeutic implications for acquired resistance and heart toxicity using targeted therapy to erbB2”
Abstracts
Comparison of EGFR Assay Results from the Community with a Central Laboratory, Poster presentation #301, 2006 ASCO GI Symposium
Evaluation of a Novel Diagnostic Algorithm for Determination of EGFR Expression, Poster presentation #302, 2006 ASCO GI Symposium
Comparison of “False Negative” EGFR Results Between Reference and Hospital Laboratories - Implications for Clinical Practice, Poster presentation #303, 2006 ASCO GI Symposium
Resistance to erbB targeted therapy in breast cancer, Poster presentation, 2005 San Antonio Breast Cancer Symposium / AACR–EORTC Molecular Targets and Cancer Therapeutics
A single arm, multicenter, open label, phase II study of lapatinib as 2nd line treatment of patients with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract, Abstract #4594, 2005 ASCO Annual Meeting
Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer, Abstract #3004, 2005 ASCO Annual Meeting
Linear Mode
